BNA’s Health Care Daily Report™ sets the standard for reliable, high-intensity coverage of breaking health care news, covering all major legal, policy, industry, and consumer developments in a...
Nov. 9 — California voters defeated a measure that would have tied what the state pays for prescription drugs to what the Department of Veterans Affairs pays.
The battle was the state’s most expensive initiative campaign. Drugmaker-fueled contributions to sink Proposition 61 exceeded $125 million, indicating just how much the industry feared a California beachhead in a nation where policy follows the winds in blowing east.
Prop. 61, with 99.7 percent of precincts reporting, was failing by 53.8 to 46.2 percent, the California Secretary of State reported. Still to be counted are provisional ballots from polling places and absentee ballots in transit.
“One takeaway is that the specter of rationing (or reduced access) remains a powerful political tool. Ohio may have a similar initiative next year, though this result may take some wind out of those sails,’” Bloomberg Intelligence analyst Brian Rye said in a Nov. 9 e-mail to Bloomberg BNA.
Prop. 61 would have affected drug spending for 4 million of California’s 39 million residents, covering the University of California, the California Public Employees’ Retirement System, public health, jails and prisons and California State University.
Drug purchases in the managed care program funded through the state Medicaid program, Medi-Cal, were exempted under the defeated measure.
“Voters did their research and recognized Prop 61 was a seriously flawed measure,” Kathy Fairbanks, No on Prop 61 Coalition spokeswoman, said in a statement. “Prop 61 was bad policy that would have harmed millions of patients, veterans, taxpayers and others in California.”
Drugmakers applauded the defeat.
“We are glad that voters recognized the flaws of Prop 61 and understood the devastating consequences it could have on veterans and patients across California,” the trade group Pharmaceutical Research and Manufacturers of America said in a statement. “Conversations about the cost of medicines are important, but Prop 61’s flawed policy was not the answer to the challenges people face accessing their medicines.”
Prop. 61 proponents applauded how well the campaign did despite being outspent 8-to-1.
“This was a tremendous uphill battle from the very start. The drug companies have managed to kill every other attempt to rein in drug prices, and last night they were able to defeat Prop. 61 by accumulating the largest war-chest ever seen against a ballot side in California’s history,” Garry South, lead strategist for Yes on 61, said in a statement.
“Yes on Prop 61/Californians for Lower Drug Prices now challenges legislators to come up with a more comprehensive solution to lower skyrocketing drug prices,” South said.
The top 10 contributors ponied up $69.8 million to defeat the measure. Pharmaceutical giants Merck & Co., Pfizer Inc. and Johnson & Johnson each contributed more than $9.3 million to defeat Prop. 61, filings with the California Secretary of State said.
Proponents, including the AIDS Healthcare Foundation and California Nurses Association, donated $18.5 million to pass Prop. 61, also called the California Drug Price Relief Act.
“Voters wisely rejected a simplistic solution to a complex problem,” Paul Howard, senior fellow at the New York think tank the Manhattan Institute, said in a statement.
“Sacramento legislators and the governor should focus their efforts on exploring new ways of paying for health care that encourage drugmakers, hospitals, and physicians to coordinate and compete on delivering the best possible health outcome for patients at the best possible price,” Howard said.
To contact the reporter on this story: Joyce E. Cutler in San Francisco at firstname.lastname@example.org
To contact the editor responsible for this story: Brian Broderick at email@example.com
Copyright © 2016 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)